
|Videos|February 17, 2023
Selecting Patients with R/R MM for Treatment With Bispecifics
Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5





























